What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “PRL3-zumab will be administered every 2-week/dose till patient progress or develops intolerable toxicity or withdraw consent. A dose at 10-days is allowed at the first 4 doses when patients had heavier tumor burden since PRL3-zumab PK t ½ = 12 days (±2 days).”In the company’s words, NCT07290088 on ClinicalTrials.gov
- Tested for
- Advanced Solid Cancers, Advanced Malignant Solid Tumor, Solid Tumor, Neovascular Age Related Macular Degeneration
- Main trialPhase 2/3
- “This is a Multi-Center, Phase II/III, open-label, single dose level (6 mg/kg) basket trial of PRL3-zumab monotherapy in solid cancer patients. The study will consist of a Screening Period (Day - 14 to Day -1) for completion of all screening assessments before the first administration of study treatment, a Treatment Period during which visits will occur every 2-week (PK T1/2 = 12 days ±2 days), once the decision to discontinue treatment for any reason, an End of Treatment (EOT) visit will be performed within 14 days ±4 days after last dose of study treatment. Safety Follow-up/EOS visit will…”In the company’s words, NCT07290088 on ClinicalTrials.gov
Other drugs for Advanced Solid Cancers
- RilvegostomigAstraZeneca · Phase 3
- UtideloneBeijing Biostar Pharmaceuticals Co., Ltd. · Phase 2
- PembrolizumabMerck & Co. · Phase 2
- DB-1303/BNT323DualityBio Inc. · Phase 1/2
- GNS561Genfit · Genoscience Pharma · Phase 1/2
- BNT329BioNTech · Phase 1/2
Coming up3
- 1 DecPhase 2 trial completes · ClinicalTrials.gov
- DecPhase 2/3 trial completes · ClinicalTrials.gov
- 7 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Dec 2026 | Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients | |
| Phase 2Active, not recruiting | 1 Jun 2026 | PRL3-Zumab in Patients With Advanced Solid Tumors | |
| Phase 2Active, not recruiting | 1 Dec 2026 | A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors | |
| Phase 1/2Recruiting | 7 Feb 2027 | A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026